| Balance Sheet Components |
Balance Sheet Components Allowance for Expected Credit Losses The following is a roll-forward of the allowances for expected credit losses related to trade accounts receivable for the three and six months ended June 30, 2026 and 2025: | | | | | | | | | | | | | Three Months Ended
June 30, | | 2026 | | 2025 | | (in thousands) | | Beginning balance | $ | 7,927 | | | $ | 7,434 | | | Provision for (reversal of) expected credit losses | (1,348) | | | 411 | | | Write-offs | (53) | | | (22) | | | Total | $ | 6,526 | | | $ | 7,823 | |
| | | | | | | | | | | | | Six Months Ended
June 30, | | 2026 | | 2025 | | (in thousands) | | Beginning balance | $ | 8,018 | | | $ | 7,259 | | Provision for (reversal of) expected credit losses | (1,126) | | | 606 | | | Write-offs | (366) | | | (42) | | | Total | $ | 6,526 | | | $ | 7,823 | |
Property and Equipment, net The Company’s property and equipment consists of the following: | | | | | | | | | | | | | | | | Useful Life | June 30,
2026 | | December 31,
2025 | | | (in thousands) | | Machinery and equipment | 3-5 years | $ | 214,823 | | | $ | 170,591 | | | Computer equipment | 3 years | 5,382 | | | 3,629 | | | Purchased and capitalized software held for internal use | 3 years | 21,561 | | | 21,195 | | | Leasehold improvements | Lesser of useful life or lease term | 76,840 | | | 62,152 | | | Construction-in-process | | 131,050 | | | 94,016 | | | Other property and equipment | | 1,269 | | | 679 | | | | 450,925 | | | 352,262 | | | Less: Accumulated depreciation and amortization | | (133,357) | | | (111,078) | | | Total property and equipment, net | | $ | 317,568 | | | $ | 241,184 | |
The Company’s long-lived assets are principally located in the United States. The Company did not incur any impairment charges during the three or six months ended June 30, 2026 or 2025. Depreciation expense for the three months ended June 30, 2026 and 2025 was $13.1 million and $8.9 million, respectively. Depreciation expense for the six months ended June 30, 2026 and 2025 was $25.7 million and $17.1 million, respectively. Other Accrued Liabilities The Company’s other accrued liabilities consisted of the following: | | | | | | | | | | | | | June 30,
2026 | | December 31,
2025 | | (in thousands) | | Legal, audit and consulting fees | $ | 53,808 | | | $ | 56,077 | | | Testing and laboratory materials from suppliers | 30,917 | | | 12,353 | | | Clinical trials and studies | 28,442 | | | 14,467 | | | Marketing and corporate affairs | 26,242 | | | 20,215 | | | Property and equipment purchases | 20,458 | | | 11,270 | | | Accrued charges for third-party testing | 18,427 | | | 20,874 | | | Operating lease liabilities, current portion | 15,123 | | | 15,581 | | | Accrued third-party service fees | 10,287 | | | 9,758 | | | Reserves for refunds to insurance carriers | 9,662 | | | 9,507 | | | Sales and income tax payable | 9,350 | | | 8,365 | | | Accrued shipping charges | 3,152 | | | 3,419 | | | Other accrued expenses | 2,588 | | | 6,773 | | | | | | | Total other accrued liabilities | $ | 228,456 | | | $ | 188,659 | |
|